Daily Stock Opinions and Ratings

Opinions

Michael Lee-Chin Hemosol HML-T DON'T BUY Mar 01, 2001

Stock price has just dropped. Still a venture company and they don't invest unless there is cash flow.

Michael Lee-Chin

Unknown

Unlock Rating

$13.630

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Very speculative. FDA trials didn't go well.

DON'T BUY

Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.

DON'T BUY

Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.

DON'T BUY

A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.

DON'T BUY

Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.

SELL

Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.

BUY

It will expire again, company has run out of money many times. Take money out, while money is on the table.

TRADE

Speculative future.

DON'T BUY

Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.

DON'T BUY

This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.

Most Recent Experts

Greg Newman

Scotia Wealth Management

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Shane Obata

Middlefield Capital

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Michael Lee-Chin Hemosol HML-T DON'T BUY Mar 01, 2001

You might be interested:

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Hemosol(HML-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Greg Newman

Stockchase Insights

Jim Cramer - Mad Money

Shane Obata

The Panic-Proof Portfolio (Stockchase Research)